Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AL-126
- Development stage
- Preclinical
- Lead developer
- ALPS Biotech
- Modality
- Small Molecules
01
Overview
AL-126 is a preclinical-stage small molecule triterpenoid isolated from the medicinal fungus *Antrodia cinnamomea* (commonly known as niu-chang-chih). Developed by ALPS Biotech, the compound acts as an inhibitor of the NLRP3 inflammasome. By suppressing NLRP3 inflammasome activation, AL-126 aims to mitigate neuroinflammation, which is a key driver in the progression of neurodegenerative disorders. In preclinical in vivo mouse models of Huntington's disease, AL-126 has demonstrated significant efficacy in delaying disease progression and improving survival rates. ALPS Biotech is also exploring its potential application in other neurodegenerative conditions, such as spinocerebellar ataxia (SCA), Alzheimer's disease, and Parkinson's disease.
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on AL-126.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AL-126.